SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ARIAD Pharmaceuticals
ARIA 23.990.0%Feb 17 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Biomaven6/6/2016 1:01:57 PM
1 Recommendation

Recommended By
scaram(o)uche

  Read Replies (1) of 4474
 
So Ariad had a very interesting poster on NGS sequencing (BY FMI) of 32 patients in their briga trials. Most startling was that 5 of the 32 patients (over 15%) had no detectable ALK fusion at baseline, and that group (not unexpectedly) did much worse than the other patients reported on - only a single PR and also the only PD in the group.

I assume the patients entered the trial based on FISH testing which can be flaky sometimes, or perhaps different parts of the biopsied specimens showed different characteristics.

I assume this issue isn't specific to Ariad's trials - it does suggest that the ALK drugs all work a bit better than reported on patients who do actually have an ALK fusion.

phx.corporate-ir.net

Note some of the patients that progressed on briga had multiple mutations - that suggests optimal to start with the best drug (which is currently briga, although alectinib is close second).
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News